OrthoTrophix Homepage

Latest News

May 12, 2020
TPX-100: OrthoTrophix Presents More Evidence for Disease Modification in Knee Osteoarthritis in a New Abstract Published in Osteoarthritis & Cartilage Journal

March 2, 2020
TPX-100: OrthoTrophix Demonstrates Evidence for Disease Modification in Knee Osteoarthritis

November 9, 2019
OrthoTrophix Presents Evidence for Disease Modification in Knee Osteoarthritis by TPX-100 at American College of Rheumatology Annual Meeting

Welcome

OrthoTrophix is a biopharmaceutical company focused on development and commercialization of revolutionary therapies for the treatment of diseases and conditions involving hard tissues such as bone and cartilage. The primary focus of OrthoTrophix is development of a first-in-class disease modifying osteoarthritis drug (DMOAD). The company’s leading therapeutic compound, TPX-100, has demonstrated a sound safety profile as well as statistically significant and clinically meaningful improvements in function and other beneficial clinical parameters in knee osteoarthritis (OA) patients. The clinical benefits are associated and correlated with reduction in pathological changes of bone and cartilage structures in the OA knee.